Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of Tamoxifen (TAM) and TAM Metabolite Concentrations with Self-Reported Side Effects of TAM in Women with Breast Cancer
Lisa Gallicchio, Gwyn A. Lord, Katherine Tkaczuk, et al.
Breast Cancer Research and Treatment (2004) Vol. 85, Iss. 1, pp. 89-97
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Adherence to Endocrine Therapy for Breast Cancer
Rowan T. Chlebowski, Michelle Geller
Oncology (2006) Vol. 71, Iss. 1-2, pp. 1-9
Closed Access | Times Cited: 251
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Sanne M. Buijs, Stijn L.W. Koolen, Ron H.J. Mathijssen, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 385-401
Open Access | Times Cited: 9
Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease
Alvin Eisner, Shiuh‐Wen Luoh
Current Eye Research (2011) Vol. 36, Iss. 10, pp. 867-885
Open Access | Times Cited: 73
Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women
David Cella, Stephanie R. Land, Chih‐Hung Chang, et al.
Breast Cancer Research and Treatment (2007) Vol. 109, Iss. 3, pp. 515-526
Closed Access | Times Cited: 69
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
Jennifer Gjerde, Jürgen Geisler, Steinar Lundgren, et al.
BMC Cancer (2010) Vol. 10, Iss. 1
Open Access | Times Cited: 64
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
Ernst A. Lien, Håvard Søiland, Steinar Lundgren, et al.
Breast Cancer Research and Treatment (2013) Vol. 141, Iss. 2, pp. 243-248
Open Access | Times Cited: 50
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer
Lorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Cancer (2005) Vol. 106, Iss. 3, pp. 505-513
Closed Access | Times Cited: 66
Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography–tandem mass spectrometry
Jennifer Gjerde, Elton R. Kisanga, Marianne Hauglid, et al.
Journal of Chromatography A (2005) Vol. 1082, Iss. 1, pp. 6-14
Closed Access | Times Cited: 62
Sensitive HPLC–PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma
Marina Venzon Antunes, Daniela Dornelles Rosa, Tamyris dos Santos Viana, et al.
Journal of Pharmaceutical and Biomedical Analysis (2012) Vol. 76, pp. 13-20
Closed Access | Times Cited: 39
Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
April N. Tucker, Katherine A. Tkaczuk, Lynn M. Lewis, et al.
Cancer Letters (2004) Vol. 217, Iss. 1, pp. 61-72
Closed Access | Times Cited: 58
A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women
Robert E. Mansel, Amit Goyal, Elisabeth Le Nestour, et al.
Breast Cancer Research and Treatment (2007) Vol. 106, Iss. 3, pp. 389-397
Closed Access | Times Cited: 48
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
Jennifer Gjerde, Sara Gandini, Aliana Guerrieri‐Gonzaga, et al.
Breast Cancer Research and Treatment (2012) Vol. 134, Iss. 2, pp. 693-700
Open Access | Times Cited: 33
Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
Anna Mueller‐Schoell, Lena Klopp‐Schulze, Werner Schroth, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 108, Iss. 3, pp. 661-670
Open Access | Times Cited: 26
Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: Application to a clinical study
Yubing Zhu, Qian Zhang, Jianjun Zou, et al.
Journal of Pharmaceutical and Biomedical Analysis (2007) Vol. 46, Iss. 2, pp. 349-355
Closed Access | Times Cited: 37
Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22
Simon Daniel Baxter, Wendy A. Teft, Yun‐Hee Choi, et al.
Breast Cancer Research and Treatment (2014) Vol. 145, Iss. 2, pp. 419-428
Closed Access | Times Cited: 29
Wide field retinal imaging and the detection of drug associated retinal toxicity
Giulia Corradetti, Sara Violanti, Adrian Au, et al.
International Journal of Retina and Vitreous (2019) Vol. 5, Iss. S1
Open Access | Times Cited: 23
Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study
Soojeong Choi, Young Jae Lee, Jae Ho Jeong, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 19
Chemoprevention of Breast Cancer by Transdermal Delivery of α-Santalol through Breast Skin and Mammary Papilla (Nipple)
Kaushalkumar Dave, Fahd M. Alsharif, Saiful Islam, et al.
Pharmaceutical Research (2017) Vol. 34, Iss. 9, pp. 1897-1907
Closed Access | Times Cited: 21
Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database
Thomas Helland, Kari Britt Hagen, Martha E. Haugstøyl, et al.
Breast Cancer Research and Treatment (2019) Vol. 177, Iss. 1, pp. 185-195
Closed Access | Times Cited: 18
Exploration of individuality in drug metabolism by high-throughput metabolomics: The fast line for personalized medicine
Oxana P. Trifonova, Richard A. Knight, Andrey Lisitsa, et al.
Drug Discovery Today (2015) Vol. 21, Iss. 1, pp. 103-110
Closed Access | Times Cited: 18
The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen
Alvin Eisner, Lisa J. Incognito
Vision Research (2005) Vol. 46, Iss. 11, pp. 1816-1822
Open Access | Times Cited: 30
Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer
Min Zhan, Jodi A. Flaws, Lisa Gallicchio, et al.
Cancer Detection and Prevention (2007) Vol. 31, Iss. 5, pp. 384-390
Closed Access | Times Cited: 25
Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors
Bettina Kotter, Fabian Engert, Winfried Krueger, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4741-4741
Open Access | Times Cited: 13
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors
Alvin Eisner, Maureen D. Toomey, Julie Falardeau, et al.
Breast Cancer Research and Treatment (2007) Vol. 106, Iss. 2, pp. 161-170
Open Access | Times Cited: 22
A review on the role of l-carnitine in the management of tamoxifen side effects in treated women with breast cancer
Nahla E. El‐Ashmawy, Rania M. Khalil
Tumor Biology (2013) Vol. 35, Iss. 4, pp. 2845-2855
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top